National Institute for Health and Clinical Excellence. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Março de 2009. www.nice.org.uk
American Psychiatric Association. DSM V: Diagnostic and Statistical Manual of Mental Disorders. 5ª edição. Arlington, American sychiatric Association, 2013
Scotish intercollegiate guidelines network (SIGN). Management of attention deficit and hyerpkinetic disorders in children and young people: A national clinical guideline. Guideline 112 Outubro de 2009.www.sign.ac.uk.
Gaub M, Carlson CL. Gender differences in ADHD: a meta-analysis and critical review.J Am Acad Child Adolesc Psychiatry 1997;36: 1036-45.
Nutt DJ, et al. Evidence-based guidelines for management of attention-deficit/ hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2007;21(1): 10-41.
Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/ hyperactivity disorder. Biol Psychiatry 2005; 57: 1313-1323.
Castellanos FX, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. JAMA 2002; 288(14): 1740-8.
Valera EM, et al. Meta-analysis of structural imaging findings in attention-deficit/ hyperactivity disorder. Biol Psychiatry 2007; 61(12): 1361-9.
Spencer TJ, et al. Overview and neurobiology of ADHD. J Clinical Psych 2002; 63(S12): 3-9.
Gillberg C, et al. Co-existing disorders in ADHD - implications for diagnosis and intervention. Eur Child Adolesc Psychiatry 2004; 13(1):I/80-I/92.
Thompson AE, et al. Children with ADHD transferring to secondary school: Potential difficulties and solutions.Clinical Child Psychology and Psychiatry 2003;8(1): 91-103.
All Party Parliamentary Group for Children (APPGC). `Every Child Matters` Green Paper. Setembro 2003.